# APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

> **NCT05701306** · PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Neuroblastoma
- Solid Tumor

## Interventions

- **DRUG:** APG-115
- **DRUG:** APG-2575

## Key facts

- **NCT ID:** NCT05701306
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-28
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701306, "APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05701306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*